To the full analysis
Jiangsu Hengrui Medicine stock: growth
600276.SSJiangsu Hengrui Medicine reported $4.71B in revenue for fiscal 2025, up 12.3% on the prior year, up 2.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
17.7%
per year from 2006 to 2025, per share 17.5%
Earnings (Annual rate)
21%
per year from 2006 to 2025, per share 20.7%
Free cash flow (Annual rate)
22.4%
per year from 2006 to 2025, per share 22.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 2.5% | 12.9% | 17.7% |
| Revenue per share | 2.1% | 12.6% | 17.5% |
| Earnings | 4.0% | 13.5% | 21.0% |
| Earnings per share | 3.5% | 13.3% | 20.7% |
| Free cash flow | 23.7% | 16.0% | 22.4% |
| Free cash flow per share | 23.1% | 15.7% | 22.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $213.32M | $30.99M | $26.98M |
| 2007 | $293.88M | $61.92M | $22.8M |
| 2008 | $358.8M | $63.43M | $937K |
| 2009 | $454.24M | $99.84M | $44.61M |
| 2010 | $561.48M | $108.6M | $14.88M |
| 2011 | $682.4M | $131.46M | −$1.94M |
| 2012 | $815.07M | $161.57M | $73.71M |
| 2013 | $930.24M | $185.67M | $136.72M |
| 2014 | $1.12B | $227.28M | $191.32M |
| 2015 | $1.4B | $325.66M | $282.41M |
| 2016 | $1.66B | $388.25M | $222.19M |
| 2017 | $2.07B | $482.38M | $324.98M |
| 2018 | $2.61B | $609.7M | $336.68M |
| 2019 | $3.49B | $799.01M | $488.21M |
| 2020 | $4.16B | $949.03M | $431.54M |
| 2021 | $3.88B | $679.37M | $383.04M |
| 2022 | $3.19B | $585.82M | −$109.01M |
| 2023 | $3.42B | $645.21M | $923.76M |
| 2024 | $4.2B | $950.25M | $817.84M |
| 2025 | $4.71B | $1.16B | $1.25B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.